Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing pivotal Phase 3
Lexicon shared details about patients in a big heart disease study. The patient types match what the study planned to test.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.